Cargando…
IL-33 released by alum is responsible for early cytokine production and has adjuvant properties
Human vaccines have used aluminium-based adjuvants (alum) for >80 years despite incomplete understanding of how alum enhances the immune response. Alum can induce the release of endogenous danger signals via cellular necrosis which elicits inflammation-associated cytokines resulting in humoral im...
Autores principales: | Rose II, William A., Okragly, Angela J., Patel, Chetan N., Benschop, Robert J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4536651/ https://www.ncbi.nlm.nih.gov/pubmed/26272855 http://dx.doi.org/10.1038/srep13146 |
Ejemplares similares
-
Nasal alum-adjuvanted vaccine promotes IL-33 release from alveolar epithelial cells that elicits IgA production via type 2 immune responses
por: Sasaki, Eita, et al.
Publicado: (2021) -
Chromatin regulates IL-33 release and extracellular cytokine activity
por: Travers, Jared, et al.
Publicado: (2018) -
Generation and Characterization of Torudokimab (LY3375880): A Monoclonal Antibody That Neutralizes Interleukin-33
por: Okragly, Angela J, et al.
Publicado: (2021) -
Interleukin-33 Contributes Toward Loss of Tolerance by Promoting B-Cell-Activating Factor of the Tumor-Necrosis-Factor Family (BAFF)-Dependent Autoantibody Production
por: Rose, William A., et al.
Publicado: (2018) -
IL-33: a novel cytokine with proinflammatory properties
por: Palmer, Gaby, et al.
Publicado: (2007)